ClinicalTrials.gg
CompletedNCT04737486Updated Mar 24, 2021

A First-in-Human Study of AV-001 in Healthy Subjects

A Phase 1 interventional study of AV-001 and Placebo in Covid19-associated ARDS, Covid19 and ARDS, sponsored by Vasomune Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-24.

Sponsored by Vasomune Therapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Mar 2021, 5 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,860 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
832nd of 1,322
48 · median 92
Started
2020
with 817 others
Phase 1
178 of 1,860
10 open now
Registered
886th of 1,860
by date

Among the 1,860 studies in COVID-19 with a site in United States, this one is the 832nd largest by enrollment of the 1,322 interventional ones that give a count, is one of 818 that started in 2020, is one of 178 in phase 1, and was the 886th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,860 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,860 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

Phase 1 randomized, double-blind, placebo-controlled single ascending dose (SAD) and multiple ascending dose (MAD) first-in-human study in healthy subjects. Safety and tolerability assessments will be conducted, and blood samples will be taken pre-dose and at several time points post-dose for pharmacokinetic (PK) and pharmacodynamics (PD) analysis.

Read the detailed description

In the SAD segment of the study, up to 4 ascending cohorts of 8 healthy subjects each will receive a single dose of study drug (AV-001 or placebo) in a sequential ascending manner. Planned doses may be adapted depending on emergent safety, tolerability and available PK data. Screening evaluations will occur from Day -28 to Day -2. Eligible subjects will be admitted to the clinical unit on Day -2. On Day 1, subjects will be randomized to AV-001 (6 subjects) or placebo (2 subjects) and receive a single dose of study drug. Subjects will be discharged on Day 2 after all post dose assessments have been completed and if there are no medical reasons for a longer stay in the clinical unit. An end of study visit will be conducted 7 to 10 days after Day 1 or at early termination.

An initial sentinel group consisting of 1 subject receiving AV-001 and 1 subject receiving placebo will proceed for each cohort prior to treatment of the remainder of the cohort. After study drug administration to the sentinel group and an appropriate safety interval (at least 24 hours and per the discretion of the Principal Investigator (PI)), the remaining 5 subjects will receive a single dose of AV-001 and 1 subject will receive placebo administered in the same manner.

PK blood samples will be collected at 15 time points relative to study drug dosing on Day 1. PD blood samples for will be collected at 6 time points on Day 1.

In the MAD segment of the study, up to 2 ascending cohorts of 8 subjects each will receive once daily doses of study drug (AV-001 or placebo) for at least 7 days in a sequential ascending manner. Planned doses may be adapted and will be determined by the safety, tolerability and PK data from the SAD part of the study. Screening evaluations will occur from Day -28 to Day -2. Eligible subjects will be admitted to the clinical unit on Day -2. On Day 1, subjects will be randomized to AV-001 (6 subjects) or placebo (2 subjects). Subjects will receive once-daily doses of study drug from Day 1 through Day 7. Subjects will be discharged on Day 8 after all post dose assessments have been completed and if there are no medical reasons for a longer stay in the clinical unit. An end of study visit will be conducted 7 to 10 days after Day 7 or at early termination.

PK blood samples will be collected at 15 time points relative to study drug dosing on Day 1 and Day 7 in addition to predose levels on Days 2 to 6. PD blood samples for will be collected at 6 time points on Day 1 and Day 7.

03

Conditions studied

  • Covid19-associated ARDS
  • Covid19
  • ARDS

Browse trials for

Keywords

  • Vascular normalization
  • Endothelial stability
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject voluntarily agrees to participate in this study and signs an Institutional Review Board (IRB) approved prior to performing any of the Screening Visit procedures
  2. Males and female subjects of nonchildbearing potential between 18 to 65 years of age, inclusive, at the Screening Visit
  3. Male subjects must agree to use a highly effective form of (e.g., abstinence, double-barrier methods, have had a vasectomy or have sexual partner(s) of nonchildbearing potential) at the time of the Screening Visit and for 30 days after the dose or last dose of IMP. Male subjects must also agree to not donate sperm for the duration of the study and until 90 days after the dose or last dose of IMP
  4. Female subjects must be nonpregnant and nonlactating and either surgically sterile (e.g., bilateral tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or for > 12 months. Postmenopausal status will be confirmed through testing of follicle-stimulating hormone (FSH) levels ≥ 40 U/mL at the Screening Visit for amenorrheic female subjects
  5. Non smokers (or other nicotine use) as determined by history (no nicotine use over the past three months) and by negative urine cotinine concentration at the Screening Visit and admission
  6. Body weight > 50 kg and \<150 kg at the Screening Visit
  7. (BMI) between 19 and 32 kg/m2, inclusive, at the Screening Visit
  8. Vital sign measurements at the Screening Visit and on Day 1 within the following ranges (measurements may be repeated once per the discretion of the Principal Investigator):

    1. Systolic blood pressure: 110 to 139 mmHg
    2. Diastolic blood pressure: 70 to 89 mmHg
    3. Pulse rate: 40 to 90 bpm
    4. Oral body temperature: 35.0°C to 37.5°C A subject should not be included if their standing vital signs (relative to sitting) show findings which, in the opinion of the Principal Investigator, are associated with the clinical manifestation of postural hypotension (i.e., absence of any other cause). These changes include either a > 20 mmHg decrease in systolic, a >10 mmHg decrease in DBP, a > 30 bpm increase in heart rate from sitting to standing or > 120 bpm
  9. Healthy, determined by prestudy medical evaluation (medical history, physical examination, vital signs, 12-lead and clinical laboratory evaluations)

Exclusion criteria

Exclusion Criteria:

  1. Subject has history or evidence of cardiovascular, hematologic, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological or psychiatric disorder(s) as determined by the Principal Investigator or designee
  2. Subject has any disorder that would interfere with the absorption, distribution, metabolism or excretion of drugs, in the opinion of the Principal Investigator
  3. Subject has a history of autonomic dysfunction (e.g., a history of fainting, orthostatic hypotension)
  4. Subject has any concurrent disease or condition that, in the opinion of the Principal Investigator, would make the subject unsuitable for participation in the clinical study
  5. Subject has history of alcohol and/or illicit drug abuse within 2 years of entry
  6. Subject has positive test for surface antigen (HBsAg), antibody (anti-HCV) or (HIV) type 1 and 2 antibodies
  7. Subject has positive breath alcohol test for ethanol at the Screening Visit or admission.
  8. Subject has positive urine drug test at the Screening Visit or admission
  9. Female subjects are breastfeeding or female subjects with a positive serum pregnancy test at the Screening Visit or admission
  10. Subject is unwilling to avoid consumption of xanthine containing products (e.g., caffeine in coffee, tea, chocolate) within 48 hours prior to admission until discharge from the clinical site
  11. Subject is unwilling to avoid use of alcohol or alcohol-containing foods, medications or beverages, within 48 hours prior to admission until discharge from the clinical site
  12. Subject has donated blood (> 500 mL) or blood products within 2 months (56 days) prior to admission
  13. Subject has used over-the-counter (OTC) medications (including vitamins), 7 days prior to admission or prescription medications or herbal remedies from 14 days prior to admission until the End-of-Study Visit. By exception, paracetamol/acetaminophen ≤ 1000 mg per day and hormonal replacement therapy are permitted
  14. Subject has participated in a clinical study or used an drug within 30 days or 5 × half lives (whichever is the longer interval) prior to the Screening Visit
  15. Subject is unwilling to abstain from vigorous exercise from 48 hours prior to admission until the End of Study Visit
  16. Subject has a history of to the study drug or any of the or to medicinal products with similar chemical structures or containing PEG (i.e., GripaNait® cough syrup, Betadine® antiseptic solution/cream)
  17. Subject is unable to understand the protocol requirements, instructions and study-related restrictions, the nature, scope and possible consequences of the clinical study
  18. Subject is unlikely to comply with the protocol requirements, instructions and study-related restrictions; e.g., uncooperative attitude, inability to return for follow-up visits and improbability of completing the clinical study
  19. Subject has a positive test result for SARS-CoV-2 before randomization
  20. Subject has previously been enrolled in this clinical study
  21. Vulnerable subjects defined as individuals whose willingness to volunteer in a clinical study may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate (e.g., persons in detention, minors and those incapable of giving consent)
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Single Ascending Dose Cohort 1-4

    Intervention: AV-001, 6 subjects per cohort will receive single doses of 1.4 µg/kg up to 56 µg/kg of AV-001 by intravenous bolus injection.

    Drug: AV-001

  • Placebo comparator
    Single Ascending Dose Cohort 1-4, Placebo

    Intervention: Placebo, 2 subjects per cohort will receive single doses of D-PBS placebo by intravenous bolus injection.

    Other: Placebo

  • Experimental
    Multiple Ascending Dose Cohort 1-2

    Intervention: AV-001, 6 subjects per cohort will receive multiple doses of 1.4 µg/kg/day up to 56 µg/kg/day of AV-001 daily for 7 consecutive days by intravenous bolus injection.

    Drug: AV-001

  • Placebo comparator
    Multiple Ascending Dose Cohort 1-2, Placebo

    Intervention: Placebo, 2 subjects per cohort will receive multiple doses of D-PBS placebo daily for 7 consecutive days by intravenous bolus injection.

    Other: Placebo

Interventions

  • DrugAV-001

    AV-001 (mpaBr) Cl for Injection 2.5 mg/mL

  • OtherPlacebo

    D-PBS

06

What researchers measure

Primary outcomes

  1. Participants experiencing drug-related adverse events

    Number of drug-related adverse events as determined by abnormal clinical laboratory tests, vitals signs, continuous blood pressure monitoring and collection (systolic, diastolic, pulse pressure, heart rate and mean arterial pressure), physical exam and ECG parameters

    Time frame: 8 days following a single intravenous dose (SAD) or 8 days following 7 consecutive daily intravenous doses (MAD)

Secondary outcomes

  1. Cmax: Maximum plasma AV-001 concentration

    Maximum plasma AV-001 concentration

    Time frame: 1 day following a single intravenous dose (SAD); 8 days following 7 consecutive daily intravenous doses (MAD)

  2. Tmax: Time of maximum plasma AV-001 concentration

    Time of maximum plasma AV-001 concentration

    Time frame: 1 day following a single intravenous dose (SAD); 8 days ollowing 7 consecutive daily intravenous doses (MAD)

  3. AUClast: AUC from predose (time 0) to the time of the last quantifiable concentration

    AUC from predose (time 0) to the time of the last quantifiable concentration

    Time frame: 1 day following a single intravenous dose (SAD); 8 days following 7 consecutive daily intravenous doses (MAD)

  4. AUCinf: AUC from predose (time 0) extrapolated to infinite time

    AUC from predose (time 0) extrapolated to infinite time

    Time frame: 1 day following a single intravenous dose (SAD); 1 day following first daily intravenous dose (MAD)

  5. AUCtau: AUC over the dose interval time

    AUC over the dose interval time

    Time frame: 8 days following 7 consecutive daily intravenous doses (MAD)

  6. λz: The terminal elimination rate

    The terminal elimination rate

    Time frame: 1 day following a single intravenous dose (SAD); 8 days following 7 consecutive daily intravenous doses (MAD)

  7. T½: Terminal elimination half-life

    Terminal elimination half-life

    Time frame: 1 day following a single intravenous dose (SAD); 8 days following 7 consecutive daily intravenous doses (MAD)

  8. CL: Total body clearance

    Total body clearance

    Time frame: 1 day following single intravenous dose (SAD); 8 days following 7 consecutive daily intravenous doses (MAD)

  9. Vz: Apparent volume of distribution

    Apparent volume of distribution

    Time frame: 1 day following a single intravenous dose (SAD); 8 days following 7 consecutive daily intravenous doses (MAD)

  10. Ctau: Trough plasma concentration

    Trough plasma concentration

    Time frame: 6 days (day 2 through day 6 of daily intravenous doses) (MAD)

  11. Rac(AUCtau), Rac(Cmax), Rac(Ctau): Accumulation ratios assessment

    Accumulation ratios assessment

    Time frame: 8 days following 7 consecutive daily intravenous doses (MAD)

  12. LM: Time-invariance ratio calculation

    Time-invariance ratio calculation

    Time frame: 8 days following 7 consecutive daily intravenous doses (MAD)

07

Study locations

1 site
  • Medpace Clinical Pharmacology Unit
    Cincinnati, Ohio 45227, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Mar 2021, 2 months.

Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's 2 months is below that.

Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 31, 2020
First posted
Feb 3, 2021
StartActual
Dec 16, 2020
Primary completionActual
Mar 10, 2021
CompletionActual
Mar 10, 2021
Last update
Mar 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04737486
Lead sponsor
Vasomune Therapeutics, Inc.
Responsible party
Sponsor
First posted
Feb 3, 2021
Start date
Dec 16, 2020
Primary completion
Mar 10, 2021
Completion
Mar 10, 2021
Last update
Mar 24, 2021

Study contacts

Leela Vrishabhendra, MD
principal investigator · Medpace, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion